Immuneering (IMRX) Cash from Operations (2020 - 2026)
Immuneering (IMRX) posted quarterly Cash from Operations of 18433444.0 for Q1 2026, down 30.91% year-over-year from 26681654.46 in Q1 2025, and down 87.32% quarter-over-quarter from 9840598.0 in Q4 2025.
Powered by 
Analysis
Immuneering (IMRX) Cash from Operations (2020 - 2026) Analysis & Trends
Immuneering's Cash from Operations history runs 7 years deep, the most recent figure standing at 18433444.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 30.91% year-over-year to 18433444.0; the TTM figure through Mar 2026 stood at 49697401.0 (up 7.26% YoY), while the FY2025 annual figure was 45344595.0, up 17.55% from the prior year.
- Cash from Operations for Q1 2026 stood at 18433444.0, down from 9840598.0 in the prior quarter.
- The five-year high for Cash from Operations was 9446124.0 in Q2 2025, with the low at 18433444.0 in Q1 2026.
- The 5-year median for Cash from Operations is 11977235.0 (2025), against an average of 12461618.18.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 100.02% in 2022, then soared 32.18% in 2025.
- Immuneering's Cash from Operations stood at 11748614.0 in 2022, then fell by 0.23% to 11775201.0 in 2023, then dropped by 23.23% to 14510513.0 in 2024, then surged by 32.18% to 9840598.0 in 2025, then slumped by 87.32% to 18433444.0 in 2026.
- Business Quant data shows IMRX's Cash from Operations at 18433444.0 in Q1 2026, 9840598.0 in Q4 2025, and 11977235.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Immuneering | 313.13 Mn | 313.13 Mn | - | -16.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.50 Mn |
| Mar 31, 2026 | -18.43 Mn |
| Dec 31, 2025 | -9.84 Mn |
| Sep 30, 2025 | -11.98 Mn |
| Jun 30, 2025 | -9.45 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -14.51 Mn |
| Sep 30, 2024 | -13.47 Mn |
| Jun 30, 2024 | -11.53 Mn |
| Mar 31, 2024 | -15.49 Mn |
| Dec 31, 2023 | -11.78 Mn |
| Sep 30, 2023 | -12.03 Mn |
| Jun 30, 2023 | -10.75 Mn |
| Mar 31, 2023 | -14.42 Mn |
| Dec 31, 2022 | -11.75 Mn |
| Sep 30, 2022 | -10.62 Mn |
| Jun 30, 2022 | -9.45 Mn |
| Mar 31, 2022 | -12.28 Mn |
| Dec 31, 2021 | -9.24 Mn |
| Sep 30, 2021 | -9.03 Mn |